Jan31Wed
Aer Lingus CEO says new service at PHL Airport will be ‘transformational’ for airline
By Kenneth Hilario, Philadelphia Business Journal
Aer Lingus is set to launch flights out of Philadelphia International Airport this year. Service out of PHL is meaningful for the Irish carrier and its travelers, both leisure and business, thanks in part to efficiency and the proximity to downtown.
Ireland’s flag carrier airline Aer Lingus in October 2017 announced it would begin nonstop flights from the Philadelphia International Airport to Dublin Airport — service that will begin operating March 25 for four days of the week before adjusting to daily service on May 18.
Reservations have been strong, with over 10,000 guests having purchased tickets for summer travel “to Ireland and beyond,” Aer Lingus CEO Stephen Kavanagh said Tuesday at an event organized by the Irish American Business Chamber & Network.
Jan31Wed
Aer Lingus cleared for takeoff at Philadelphia airport
By Andrew Maykuth, Philly.com
Ireland’s Aer Lingus is set to launch nonstop service in March from Philadelphia to Dublin, and is positioning itself as a value airline providing connecting service to the United Kingdom, Europe, and Abu Dhabi.
“We want to be the leading value carrier across the North Atlantic,” chief executive Stephen Kavanagh told a packed audience of the Irish American Business Chamber and Network at the Pyramid Club on Tuesday.
Kavanagh cited the large number of Irish Americans in the region as an impetus for making Philadelphia its 12th destination in North America. Irish companies also have more than 232 offices or facilities in Pennsylvania, he said, and Aer Lingus is courting them with offers of corporate deals.
Jan29Mon
Almac Group Appoints Dr Stefan Mix as Head of Biocatalysis
Craigavon, N.I., 29 January 2018 – Almac Group, the global contract development and manufacturing organisation, has announced the appointment of Dr Stefan Mix to the position of Head of Biocatalysis, effective from 2 January 2018.
Stefan joined the Almac Sciences business in April 2005 as a chemist working in the lab on process development projects for chiral materials and has been part of the biocatalysis team since its beginnings. He has gained broad industrial experience including applications of biocatalysis, crystallisation development, process development for chiral building blocks and APIs, and technology transfer to manufacturing network partners, and was promoted to Biocatalysis Team Leader in 2012. All this time he has played a significant role in the development of Almac Sciences’ Biocatalysis Technology platform which has seen rapid growth and has multiple applications across a range of project scales and industry sectors.
Jan26Fri
Jan25Thu
$105M deal: Spark enters into licensing deal with Novartis
By John George, Philadelphia Business Journal
Spark Therapeutics
has entered into a deal to license the rights to its new gene therapy treatment Luxturna outside the United States for $105 million upfront, and the potential to earn another $65 million in milestone payments.
Philadelphia-based Spark (NASDAQ: ONCE) signed the deal with Novartis (NYSE: NVS). Luxturna was approved by the Food and Drug Administration last month as a one-time treatment for a type of inherited retinal disorder that causes blindness.
Under the agreement, Philadelphia-based Spark will retain regulatory responsibility for obtaining European Medicines Agency approval for Luxturna. Spark Therapeutics also entered into a separate agreement to manufacture and supply investigational voretigene neparvovec, the treatment it markets in the United States under the brand name Luxturna, to Novartis. Click HERE to read more.
